The FDA assessed the safety and usefulness of atidarsagene autotemcel according to data from 37 small children who gained atidarsagene autotemcel in two solitary-arm, open-label medical trials and in an expanded entry software.[7] Small children who acquired therapy with atidarsagene autotemcel were compared to untreated small children (organic rec